HK Stock Market Move | GIANT BIOGENE (02367) falls by over 4% again in the short term, with performance fluctuating due to public opinion. Annual net profit decreases by 7.15% year-on-year.

GIANT BIOGENE (02367) fell more than 4% again, as of the time of writing, down 4.69% to HK$29.26, with a turnover of HK$1.41 billion. On the news front, GIANT BIOGENE released its annual performance. During the period, it achieved operating income of HK$5.519 billion, a year-on-year decrease of 0.37%; and a net profit attributable to the parent company of HK$1.915 billion, a year-on-year decrease of 7.15%. China International Capital Corporation (CICC) issued a report stating that GIANT BIOGENE's performance in 2025 meets the bank's expectations. Due to external impacts and intensified competition, the bank lowered its net profit forecast for 2026-2027, maintaining an "outperform" rating and lowering the target price by 13% to HK$49. Soochow pointed out that as a leader in China's recombinant collagen field, the company's brand strength and product power in the skincare sector are solid, with two new products approved for market launch in the medical beauty field, which are expected to open up growth space. Considering the increasing industry competition since the second half of 2025, combined with the short-term impact of public opinion on the company's sales, the bank lowered its profit forecast for the company for 2026-2027. Short-term public opinion fluctuations may affect performance, but the company's leading position is outstanding in the long term, with expectations for a gradual recovery in performance in 2026, maintaining a "buy" rating.